Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Pregnancy Hypertens. 2022 Dec;30:82-86. doi: 10.1016/j.preghy.2022.08.010. Epub 2022 Aug 31.
In response to 2013 guidelines for hypertensive disorders of pregnancy (HDP), our study examined changes in antenatal management and postpartum readmission (PPR) over time.
This is a retrospective cohort study of individuals diagnosed antenatally with HDP who delivered at a tertiary care center from 2012 to 2017.
The primary outcome was postpartum readmission for HDP in 2012-2013 vs 2014-2017. Secondary outcomes included intravenous magnesium administration and prescription for oral (PO) antihypertensive medication during delivery admission. Multivariable logistic regression models assessed differences in outcomes over time, adjusted for age, race, and payer status, for HDP with and without severe features, defined by ACOG criteria.
Of 5,300 eligible individuals, 73.5 % had HDP without severe features and 26.5 % had severe features. The PPR frequency in this cohort was 1.1 % (N = 59). There was no difference in PPR for individuals with HDP without severe features (aOR 0.73; 95 % CI 0.28-1.88) or with severe features (aOR 1.30; 95 % CI 0.50-3.39) by epoch. Magnesium administration for HDP with severe features remained below 80 % over time. Magnesium administration for HDP without severe features and discharge prescriptions for PO medications for HDP with severe features were lower after 2013. Neither magnesium administration nor discharge prescriptions were associated with decreased odds of PPR.
Although there was no difference in PPR for HDP after 2013, there were changes in antenatal management of HDP, including decreased magnesium administration for individuals with HDP without severe features and PO medication for individuals with severe features.
针对 2013 年妊娠高血压疾病(HDP)指南,本研究旨在观察一段时间内产前管理和产后再入院(PPR)的变化。
这是一项回顾性队列研究,纳入了 2012 年至 2017 年在三级医疗中心产前诊断为 HDP 并分娩的个体。
主要结局是 2012-2013 年与 2014-2017 年 HDP 的产后再入院。次要结局包括分娩期间静脉内镁的使用和口服(PO)降压药物的处方。多变量逻辑回归模型评估了在有和无 ACOG 标准定义的严重特征的 HDP 中,随着时间的推移,在年龄、种族和支付人状态调整后的结局差异。
在 5300 名符合条件的个体中,73.5%的个体患有无严重特征的 HDP,26.5%的个体患有严重特征的 HDP。该队列的 PPR 频率为 1.1%(N=59)。无严重特征的 HDP 患者(aOR 0.73;95%CI 0.28-1.88)或有严重特征的 HDP 患者(aOR 1.30;95%CI 0.50-3.39)的 PPR 无差异按时间。严重特征的 HDP 患者的镁治疗始终低于 80%。无严重特征的 HDP 患者的镁治疗和严重特征的 HDP 患者的 PO 药物出院处方在 2013 年后降低。镁治疗和出院处方均与 PPR 几率的降低无关。
尽管 2013 年后 HDP 的 PPR 没有差异,但 HDP 的产前管理发生了变化,包括无严重特征的 HDP 患者的镁治疗减少和严重特征的 HDP 患者的 PO 药物治疗减少。